Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Hess

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Blood Advances|March 18, 2024
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapyMegan Melody, Narendranath Epperla, Geoffrey Shouse, et al.
Blood Cancer Journal|March 27, 2025
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapyReem Karmali, Geoffrey Shouse, Pallawi Torka, et al.
Cancers|July 29, 2025
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CARTNicole J Altomare, Megan M Herr, Nisha M Nair, et al.
The Lancet. Haematology|June 18, 2024
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre studyKim M Linton, Umberto Vitolo, Wojciech Jurczak, et al.
Journal of Hematology & Oncology|November 10, 2023
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Lei Feng, Nirav N Shah, et al.
Blood Advances|October 22, 2025
Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortiumMegan Melody, Natalie Grover, Stephanie Franco, et al.
Blood Advances|March 26, 2024
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapyReem Karmali, Rushad Machhi, Narendranath Epperla, et al.
Blood Advances|September 12, 2022
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHLJoanna Zurko, Imran Nizamuddin, Narendranath Epperla, et al.
Blood Advances|January 17, 2020
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsPallawi Torka, Shalin K Kothari, Suchitra Sundaram, et al.
Blood Advances|February 23, 2022
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphomaJuan Pablo Alderuccio, Luca Arcaini, Marcus P Watkins, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Blood Advances|March 18, 2024
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapyMegan Melody, Narendranath Epperla, Geoffrey Shouse, et al.
Blood Cancer Journal|March 27, 2025
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapyReem Karmali, Geoffrey Shouse, Pallawi Torka, et al.
Cancers|July 29, 2025
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CARTNicole J Altomare, Megan M Herr, Nisha M Nair, et al.
The Lancet. Haematology|June 18, 2024
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre studyKim M Linton, Umberto Vitolo, Wojciech Jurczak, et al.
Journal of Hematology & Oncology|November 10, 2023
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Lei Feng, Nirav N Shah, et al.
Blood Advances|October 22, 2025
Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortiumMegan Melody, Natalie Grover, Stephanie Franco, et al.
Blood Advances|March 26, 2024
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapyReem Karmali, Rushad Machhi, Narendranath Epperla, et al.
Blood Advances|September 12, 2022
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHLJoanna Zurko, Imran Nizamuddin, Narendranath Epperla, et al.
Blood Advances|January 17, 2020
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsPallawi Torka, Shalin K Kothari, Suchitra Sundaram, et al.
Blood Advances|February 23, 2022
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphomaJuan Pablo Alderuccio, Luca Arcaini, Marcus P Watkins, et al.
Pageof 5